Barclays PLC Lucid Diagnostics Inc. Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Barclays PLC holds 1,584 shares of LUCD stock, worth $2,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,584

Holding current value

$2,027

% of portfolio

0.0%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.79 - $1.59 $1,251 - $2,518	1,584 New	1,584 $2,000
Q2 2022 Aug 12, 2022	SELL	$1.73 - $3.44 $1,422 - $2,827	-822 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.85 - $5.24 $2,342 - $4,307	822 New	822 $2,000

Others Institutions Holding LUCD

# of Institutions

Shares Held

9.45M

Call Options Held

Put Options Held

Masters Capital Management LLC Atlanta, GA

2.73M
Shares

$3.49 Million
0.21% of portfolio
Alyeska Investment Group, L.P. Chicago, IL

1.89M
Shares

$2.42 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

889K
Shares

$1.14 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

459K
Shares

$587,603
0.0% of portfolio
Luminus Management LLC Houston, TX

457K
Shares

$584,504
0.62% of portfolio

View Full List

About Lucid Diagnostics Inc.

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $49.4M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

More about LUCD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account